MENOMUNE VACCINE

देश: सिंगापुर

भाषा: अंग्रेज़ी

स्रोत: HSA (Health Sciences Authority)

सक्रिय संघटक:

MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A, C, Y, W-135

थमां उपलब्ध:

SANOFI-AVENTIS SINGAPORE PTE. LTD.

ए.टी.सी कोड:

J07AH04

डोज़:

50 mcg/ps/0.5 ml

फार्मास्यूटिकल फॉर्म:

INJECTION, POWDER, FOR SOLUTION

रचना:

MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A, C, Y, W-135 50 mcg/ps/0.5 ml

प्रशासन का मार्ग:

SUBCUTANEOUS

प्रिस्क्रिप्शन प्रकार:

Prescription Only

द्वारा बनाया गया:

SANOFI PASTEUR INC.

प्राधिकरण का दर्जा:

ACTIVE

प्राधिकरण की तारीख:

1998-08-22

सूचना पत्रक

 
1 

MENINGOCOCCAL POLYSACCHARIDE 
VACCINE, GROUPS A, C, Y AND 
W-135 COMBINED 
MENOMUNE
®
 – A/C/Y/W-135 

1. INDICATIONS AND USAGE 

Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, is indicated for 
active immunization against invasive meningococcal
disease caused by these serogroups. 

Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined may be used to 
prevent and control outbreaks of serogroup C meningococcal
disease. 

For evaluation and management of suspected outbreaks, it is recommended that the health-care 
workers consult the MMWR for guidance. 

Routine vaccination is recommended
for the following high-risk groups: 
1. Deficiencies in late Complement components (C3, C5-C9). 
2. Functional or actual asplenia. 
3. Persons with laboratory or industrial
exposure to _N meningitidis _aerosols. 
4.  Travelers  to,  and  residents  of,  hyperendemic  areas  such  as  sub-Saharan  Africa.  For 
information concerning geographic areas for which vaccination is recommended, contact CDC at 
404-332-4559. 

The  American  College  Health  Association  (ACHA)  also  recommends  that  college  students 
consider vaccination to reduce the risk for potentially fatal
meningococcal disease. 

Vaccinations  also  should  be  considered  for  household  or  institutional  contacts  of  persons  with 
meningococcal  disease  and  for  medical  and  laboratory  personnel  at  risk  of  exposure  to 
meningococcal disease. 

This  vaccine  will  not  stimulate  protection  against  infections  caused  by  organisms  other  than 
Groups A, C, Y and W-135 meningococci. 

Protective antibody levels may be achieved within 7 to 10
days after vaccination. 

Menomune – A/C/Y/W-135 vaccine is not to be used for treatment
of ac

उत्पाद विशेषताएं

1
MENINGOCOCCAL POLYSACCHARIDE
VACCINE, GROUPS A, C, Y AND
W-135 COMBINED
MENOMUNE
®
– A/C/Y/W-135
1. INDICATIONS AND USAGE
Menomune
®
-A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and
W-
135 Combined, is indicated for active immunization against invasive
meningococcal disease
caused by these serogroups.
Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135
Combined may be used to
prevent and control outbreaks of serogroup C meningococcal disease.
For evaluation and management of suspected outbreaks, it is
recommended that the health-care
workers consult the MMWR for guidance.
Routine vaccination is recommended for the following high-risk groups:
1. Deficiencies in late Complement components (C3, C5-C9).
2. Functional or actual asplenia.
3. Persons with laboratory or industrial exposure to
_N meningitidis _
aerosols.
4.
Travelers
to,
and
residents
of,
hyperendemic
areas
such
as
sub-Saharan
Africa.
For
information concerning geographic areas for which vaccination is
recommended, contact CDC at
404-332-4559.
The American College Health Association (ACHA) also recommends that
college students
consider vaccination to reduce the risk for potentially fatal
meningococcal disease.
Vaccinations also should be considered for household or institutional
contacts of persons with
meningococcal
disease
and
for
medical
and
laboratory
personnel
at
risk
of
exposure
to
meningococcal disease.
This vaccine will not stimulate protection against infections caused
by organisms other than
Groups A, C, Y and W-135 meningococci.
Protective antibody levels may be achieved within 7 to 10 days after
vaccination.
Menomune – A/C/Y/W-135 vaccine is not to be used for treatment of
actual infection.
Menomune – A/C/Y/W-135 vaccine will not protect against other
etiologic agents, including
_N _
_meningitidis _
serogroup B, that cause meningitis.
Menomune – A/C/Y/W-135 vaccine is not indicated for infants and
children younger than 2
years of age except as short-term protection of infants 3 months and
older agai